GLP-1 maintenance tips: what TikTok gets right and wrong

What did @chaseveryday actually say?

In month 11 of weight maintenance on a GLP-1 medication, @chaseveryday describes titrating down from 15mg to 6mg weekly injections after reaching their goal weight. Their core advice: "you have to increase your calories as you decrease your medication" to avoid continued weight loss. They also flag that extending injection intervals, even to 10 days or three weeks, causes food noise to return for them personally.

This is anecdotal but grounded. They're not selling anything or prescribing to others. They're describing their own experience on what appears to be tirzepatide, given the milligram dosing. The disclaimer to consult a provider is present. That counts for something on a platform where it's usually absent.

Does the science back this up?

Yes, more than you'd expect from a TikTok video. The calorie-deficit point is the strongest claim here, and it holds up.

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide produced significant weight loss even during dose reduction phases, meaning the drug's effect on appetite suppression can outlast the dose decrease temporarily. If caloric intake doesn't increase to match the metabolic adjustment, continued weight loss is a real outcome, not hypothetical.

On half-life: tirzepatide has a half-life of approximately five days (Eli Lilly prescribing information). The creator's description of a "switch that flips" around day seven is consistent with plasma concentration data. Once levels drop below therapeutic range, appetite-suppressing effects diminish. This is pharmacology, not anecdote.

The concept of finding a maintenance dose, rather than stopping entirely, is supported by the SURMOUNT-4 trial (Aronne et al., 2024, JAMA), which showed significant weight regain after discontinuation, reinforcing the case for long-term lower-dose continuation.

What did they get wrong (or right)?

Mostly right, with one important gap. The calorie-increase-during-dose-taper point is genuinely useful and undersaid in most GLP-1 content. Credit where it's due.

What's missing: the creator doesn't mention that continued weight loss during dose reduction can also reflect muscle loss, not just fat loss, if protein intake and resistance training aren't actively maintained. Research from Bikou et al. (2024, Obesity Reviews) flagged that GLP-1 users without structured exercise programs lose disproportionate lean mass. That's not a minor detail in a maintenance conversation.

The 6mg dose framing is fine as personal experience, but listeners may interpret specific milligram numbers as guidance. They're not. Appropriate maintenance doses vary by individual response, comorbidities, and tolerability. This platform cannot and does not recommend any specific dose.

The "food noise" framing is accurate shorthand for the hedonic hunger suppression GLP-1 medications provide, consistent with how researchers like Rubino et al. (2021, Lancet) describe reduced food preoccupation in clinical responders.

What should you actually know?

Three things matter here if you're entering GLP-1 maintenance.

First, the calorie point is real and underappreciated. Most people focus on the dose. The dose change affects appetite, but the actual weight trajectory is still governed by energy balance. If your appetite stays suppressed even on a lower dose, you may continue losing weight without intending to.

Second, extending injection intervals to save money or stretch supply is common but not risk-free. The half-life data supports the creator's observation that food noise returns, but inconsistent dosing can also affect glycemic control in people using these medications for type 2 diabetes, not just weight management.

Third, maintenance is not a solved problem. The SURMOUNT-4 data shows most people regain weight after stopping entirely. Whether indefinite lower-dose continuation is the right strategy depends on your individual health profile, something a video cannot assess and this platform will not speculate on. Talk to the provider who knows your chart.